Needham & Company LLC restated their hold rating on shares of Inogen (NASDAQ:INGN - Free Report) in a report released on Wednesday,Benzinga reports.
Separately, StockNews.com raised Inogen from a "hold" rating to a "buy" rating in a research note on Monday, February 10th.
View Our Latest Stock Report on INGN
Inogen Stock Up 4.8 %
Shares of NASDAQ INGN traded up $0.38 during trading on Wednesday, reaching $8.33. The company had a trading volume of 408,849 shares, compared to its average volume of 309,250. Inogen has a 12-month low of $6.14 and a 12-month high of $13.33. The stock has a market cap of $198.40 million, a PE ratio of -3.70 and a beta of 1.02. The business's 50-day moving average is $10.18 and its 200 day moving average is $10.21.
Institutional Investors Weigh In On Inogen
Several institutional investors have recently modified their holdings of the business. PharVision Advisers LLC purchased a new stake in shares of Inogen during the fourth quarter valued at $173,000. Squarepoint Ops LLC purchased a new stake in shares of Inogen during the fourth quarter valued at $424,000. State of Wyoming boosted its position in shares of Inogen by 520.3% during the fourth quarter. State of Wyoming now owns 20,229 shares of the medical technology company's stock valued at $186,000 after buying an additional 16,968 shares during the last quarter. Millennium Management LLC boosted its position in shares of Inogen by 162.5% during the fourth quarter. Millennium Management LLC now owns 143,653 shares of the medical technology company's stock valued at $1,317,000 after buying an additional 88,924 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of Inogen by 4.4% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 303,522 shares of the medical technology company's stock valued at $2,783,000 after buying an additional 12,654 shares during the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.
Inogen Company Profile
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
